Back to Browse Journals » Cancer Management and Research » Volume 3

From antiangiogenesis to hypoxia: current research and future directions

Authors Christopher Rice, L Eric Huang

Published Date December 2010 Volume 2011:3 Pages 9—16


Published 20 December 2010

Christopher Rice1, L Eric Huang1,2
1Department of Neurosurgery, 2Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA

Abstract: Angiogenesis has long been recognized as an essential element in tumor growth. Since the conception of antiangiogenesis for cancer therapeutics, great strides have been made in understanding the molecular biology underlying angiogenesis, both in cancer and in physiology. By capitalizing on these advancements through bench-to-bedside research, potent antiangiogenic agents have been developed and tested. To date, the clinical results of most of these antiangiogenic agents have not met expectations. Even with the most successful agents, such as bevacizumab, used either as single agents or in combination with chemotherapy, gains in overall survival of cancer patients have been modest in most cases. In this article, the authors present the evolving views of antiangiogenic therapy, review recent experimental and clinical studies on antiangiogenesis, and address the fundamental role of hypoxia in tumor progression, which may be key to improving the efficacy of antiangiogenic therapy.

Keywords: antiangiogenesis, genetic alteration, hypoxia, tumor progression

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Complex role of HIF in cancer: the known, the unknown, and the unexpected

Tiburcio PD, Choi H, Huang LE

Hypoxia 2014, 2:59-70

Published Date: 18 June 2014

Readers of this article also read:

A case of radial keratoneuritis in non-Acanthamoeba keratitis

Mutoh T, Matsumoto Y, Chikuda M

Clinical Ophthalmology 2012, 6:1535-1538

Published Date: 21 September 2012

Hibiscus sabdariffa L., roselle calyx, from ethnobotany to pharmacology

Carvajal-Zarrabal O, Barradas-Dermitz DM, Orta-Flores Z, Hayward-Jones PM, Nolasco-Hipólito C, Aguilar-Uscanga MG, Miranda-Medina A, Bujang KB

Journal of Experimental Pharmacology 2012, 4:25-39

Published Date: 29 February 2012

Transforming nanostructured chitin from crustacean waste into beneficial health products: a must for our society

Morganti P, Morganti GGM, Morganti AAM

Nanotechnology, Science and Applications 2011, 4:123-129

Published Date: 6 December 2011

Emerging options in growth hormone therapy: an update

Kemp SF, Frindik JP

Drug Design, Development and Therapy 2011, 5:411-419

Published Date: 30 August 2011

Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management

Emanuele Neri, Lorenzo Faggioni, Lorenzo Cini, et al

Cancer Management and Research 2011, 3:17-24

Published Date: 30 December 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009